Papers › migraines › 5131925

Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study

The lancet. Gastroenterology & hepatology · 01-10-2016 · 5131925 on PMC →

91 citations FWCI 9.99 Hepatitis C virus research Trend

Citation data as of 2026-04-12 (OpenAlex).

Extracted findings

This paper hasn't been extracted into the knowledge graph yet. We're working through the corpus — 5131925 is in the queue.

In the meantime: Browse migraines papers → · Ask about this topic → · Explore the graph →